DSCAM-AS1-Driven Proliferation of Breast Cancer Cells Involves Regulation of Alternative Exon Splicing and 3′-End Usage

DSCAM-AS1 is a cancer-related long noncoding RNA with higher expression levels in Luminal A, B, and HER2-positive Breast Carcinoma (BC), where its expression is strongly dependent on Estrogen Receptor Alpha (ERα). DSCAM-AS1 expression is analyzed in 30 public datasets and, additionally, by qRT-PCR in tumors from 93 BC patients, to uncover correlations with clinical data. Moreover, the effect of DSCAM-AS1 knockdown on gene expression and alternative splicing is studied by RNA-Seq in MCF-7 cells. We confirm DSCAM-AS1 overexpression in high grade Luminal A, B, and HER2+ BCs and find a significant correlation with disease relapse. In total, 908 genes are regulated by DSCAM-AS1-silencing, primarily involved in the cell cycle and inflammatory response. Noteworthily, the analysis of alternative splicing and isoform regulation reveals 2085 splicing events regulated by DSCAM-AS1, enriched in alternative polyadenylation sites, 3′UTR (untranslated region) shortening and exon skipping events. Finally, the DSCAM-AS1-interacting splicing factor heterogeneous nuclear ribonucleoprotein L (hnRNPL) is predicted as the most enriched RBP for exon skipping and 3′UTR events. The relevance of DSCAM-AS1 overexpression in BC is confirmed by clinical data and further enhanced by its possible involvement in the regulation of RNA processing, which is emerging as one of the most important dysfunctions in cancer.

[1]  Nuno A. Fonseca,et al.  Cancer LncRNA Census reveals evidence for deep functional conservation of long noncoding RNAs in tumorigenesis , 2020, Communications Biology.

[2]  S. Mirarab,et al.  Sequence Analysis , 2020, Encyclopedia of Bioinformatics and Computational Biology.

[3]  A. Jemal,et al.  Cancer statistics, 2020 , 2020, CA: a cancer journal for clinicians.

[4]  F. Slack,et al.  The Role of Non-coding RNAs in Oncology , 2019, Cell.

[5]  M. Zavolan,et al.  Alternative cleavage and polyadenylation in health and disease , 2019, Nature Reviews Genetics.

[6]  G. Giamas,et al.  Endocrine Resistance in Hormone Receptor Positive Breast Cancer–From Mechanism to Therapy , 2019, Front. Endocrinol..

[7]  L. Maquat,et al.  Quality and quantity control of gene expression by nonsense-mediated mRNA decay , 2019, Nature Reviews Molecular Cell Biology.

[8]  Olga Tanaseichuk,et al.  Metascape provides a biologist-oriented resource for the analysis of systems-level datasets , 2019, Nature Communications.

[9]  Konstantinos D. Tsirigos,et al.  SignalP 5.0 improves signal peptide predictions using deep neural networks , 2019, Nature Biotechnology.

[10]  C. Mathias,et al.  Long non‐coding RNAs differential expression in breast cancer subtypes: What do we know? , 2019, Clinical genetics.

[11]  Zhiyun Ge,et al.  hnRNP L‐dependent protection of normal mRNAs from NMD subverts quality control in B cell lymphoma , 2018, The EMBO journal.

[12]  Thalia E. Chan,et al.  Single-cell transcriptomics reveals multi-step adaptations to endocrine therapy , 2018, Nature Communications.

[13]  Xiao-En Xu,et al.  DSCAM‐AS1 regulates the G1/S cell cycle transition and is an independent prognostic factor of poor survival in luminal breast cancer patients treated with endocrine therapy , 2018, Cancer medicine.

[14]  Silvio C. E. Tosatto,et al.  The Pfam protein families database in 2019 , 2018, Nucleic Acids Res..

[15]  Jian-feng Dong,et al.  LncRNA DSCAM‐AS1 acts as a sponge of miR‐137 to enhance Tamoxifen resistance in breast cancer , 2018, Journal of cellular physiology.

[16]  Albin Sandelin,et al.  IsoformSwitchAnalyzeR: Analysis of changes in genome-wide patterns of alternative splicing and its functional consequences , 2018, bioRxiv.

[17]  Inanc Birol,et al.  Recurrent tumor-specific regulation of alternative polyadenylation of cancer-related genes , 2018, BMC Genomics.

[18]  Jianzhong Su,et al.  3′ UTR shortening represses tumor-suppressor genes in trans by disrupting ceRNA crosstalk , 2018, Nature Genetics.

[19]  X. An,et al.  The prognostic significance of topoisomerase II alpha protein in early stage luminal breast cancer , 2018, BMC Cancer.

[20]  Marco Beccuti,et al.  Luminal breast cancer-specific circular RNAs uncovered by a novel tool for data analysis , 2018, Oncotarget.

[21]  V. Miano,et al.  Luminal lncRNAs Regulation by ERα-Controlled Enhancers in a Ligand-Independent Manner in Breast Cancer Cells , 2018, International journal of molecular sciences.

[22]  H. Margalit,et al.  Post-transcriptional 3´-UTR cleavage of mRNA transcripts generates thousands of stable uncapped autonomous RNA fragments , 2017, Nature Communications.

[23]  Wolfgang Huber,et al.  Alternative start and termination sites of transcription drive most transcript isoform differences across human tissues , 2017, Nucleic acids research.

[24]  P. Barbry,et al.  Post-transcriptional gene silencing mediated by microRNAs is controlled by nucleoplasmic Sfpq , 2017, Nature Communications.

[25]  Wei Li,et al.  TC3A: The Cancer 3′ UTR Atlas , 2017, Nucleic Acids Res..

[26]  Yanyan Ping,et al.  Oncogenic long noncoding RNA landscape in breast cancer , 2017, Molecular Cancer.

[27]  Robert J. Weatheritt,et al.  Whippet: an efficient method for the detection and quantification of alternative splicing reveals extensive transcriptomic complexity , 2017, bioRxiv.

[28]  M. Loda,et al.  Genome-wide CRISPR screen identifies HNRNPL as a prostate cancer dependency regulating RNA splicing , 2017, Proceedings of the National Academy of Sciences.

[29]  Ge Gao,et al.  CPC2: a fast and accurate coding potential calculator based on sequence intrinsic features , 2017, Nucleic Acids Res..

[30]  Timothy R. Hughes,et al.  RNAcompete methodology and application to determine sequence preferences of unconventional RNA-binding proteins. , 2017, Methods.

[31]  Garrett M. Dancik,et al.  shinyGEO: a web-based application for analyzing gene expression omnibus datasets , 2016, Bioinform..

[32]  R. Jia,et al.  HnRNP L is important for the expression of oncogene SRSF3 and oncogenic potential of oral squamous cell carcinoma cells , 2016, Scientific Reports.

[33]  A. Chinnaiyan,et al.  The lncRNA landscape of breast cancer reveals a role for DSCAM-AS1 in breast cancer progression , 2016, Nature Communications.

[34]  Allison P. Heath,et al.  Toward a Shared Vision for Cancer Genomic Data. , 2016, The New England journal of medicine.

[35]  Y. Pawitan,et al.  Comprehensive landscape of subtype-specific coding and non-coding RNA transcripts in breast cancer , 2016, Oncotarget.

[36]  Gianluca Bontempi,et al.  Portraying breast cancers with long noncoding RNAs , 2016, Science Advances.

[37]  F. Robert,et al.  Heterogeneous Nuclear Ribonucleoprotein L is required for the survival and functional integrity of murine hematopoietic stem cells , 2016, Scientific Reports.

[38]  R. Lothe,et al.  Aberrant RNA splicing in cancer; expression changes and driver mutations of splicing factor genes , 2016, Oncogene.

[39]  J. Valcárcel,et al.  Large-scale analysis of genome and transcriptome alterations in multiple tumors unveils novel cancer-relevant splicing networks , 2016, Genome research.

[40]  M. Robinson,et al.  Differential analyses for RNA-seq: transcript-level estimates improve gene-level inferences , 2015, F1000Research.

[41]  Y. Mo,et al.  Linc-RoR promotes c-Myc expression through hnRNP I and AUF1 , 2015, Nucleic acids research.

[42]  I. Castellano,et al.  Luminal long non-coding RNAs regulated by estrogen receptor alpha in a ligand-independent manner show functional roles in breast cancer , 2015, Oncotarget.

[43]  Gary K. Schwartz,et al.  Alternative transcription initiation leads to expression of a novel ALK isoform in cancer , 2015, Nature.

[44]  A. Chinnaiyan,et al.  Long noncoding RNAs in cancer: from function to translation. , 2015, Trends in cancer.

[45]  Christos G. Gkogkas,et al.  G3BP1 promotes stress-induced RNA granule interactions to preserve polyadenylated mRNA , 2015, The Journal of cell biology.

[46]  Kai Blin,et al.  DoRiNA 2.0—upgrading the doRiNA database of RNA interactions in post-transcriptional regulation , 2014, Nucleic Acids Res..

[47]  Chaolin Zhang,et al.  Loss of MBNL leads to disruption of developmentally regulated alternative polyadenylation in RNA-mediated disease. , 2014, Molecular cell.

[48]  Zhenbo Hou,et al.  Profiling of alternative polyadenylation sites in luminal B breast cancer using the SAPAS method , 2014, International journal of molecular medicine.

[49]  A. Mele,et al.  Loss of the multifunctional RNA-binding protein RBM47 as a source of selectable metastatic traits in breast cancer , 2014, eLife.

[50]  C. Ballaré,et al.  Genome-wide activity of unliganded estrogen receptor-α in breast cancer cells , 2014, Proceedings of the National Academy of Sciences.

[51]  Julian König,et al.  Crosslinking-immunoprecipitation (iCLIP) analysis reveals global regulatory roles of hnRNP L , 2014, RNA biology.

[52]  M. J. Mallory,et al.  Transcriptome-Wide RNA Interaction Profiling Reveals Physical and Functional Targets of hnRNP L in Human T Cells , 2013, Molecular and Cellular Biology.

[53]  S. Fuqua,et al.  RNA sequencing of cancer reveals novel splicing alterations , 2013, Scientific Reports.

[54]  Benjamin E. Gross,et al.  Integrative Analysis of Complex Cancer Genomics and Clinical Profiles Using the cBioPortal , 2013, Science Signaling.

[55]  Colin N. Dewey,et al.  RSEM: accurate transcript quantification from RNA-Seq data with or without a reference genome , 2011, BMC Bioinformatics.

[56]  Seneca L. Bessling,et al.  Steroid hormone modulation of RET through two estrogen responsive enhancers in breast cancer. , 2011, Human molecular genetics.

[57]  Leland Wilkinson,et al.  ggplot2: Elegant Graphics for Data Analysis by WICKHAM, H. , 2011 .

[58]  William Stafford Noble,et al.  FIMO: scanning for occurrences of a given motif , 2011, Bioinform..

[59]  Olufunmilayo I Olopade,et al.  MYC and Breast Cancer. , 2010, Genes & cancer.

[60]  Brendan J. Frey,et al.  Deciphering the splicing code , 2010, Nature.

[61]  Jeong-Hwa Lee,et al.  Effect of Modulation of hnRNP L Levels on the Decay of bcl-2 mRNA in MCF-7 Cells. , 2010, The Korean journal of physiology & pharmacology : official journal of the Korean Physiological Society and the Korean Society of Pharmacology.

[62]  C. Mayr,et al.  Widespread Shortening of 3′UTRs by Alternative Cleavage and Polyadenylation Activates Oncogenes in Cancer Cells , 2009, Cell.

[63]  David J. Elliott,et al.  Alternative splicing and biological heterogeneity in prostate cancer , 2009, Nature Reviews Urology.

[64]  C. Plass,et al.  The functional consequences of alternative promoter use in mammalian genomes. , 2008, Trends in genetics : TIG.

[65]  Monika Heiner,et al.  Intronic CA‐repeat and CA‐rich elements: a new class of regulators of mammalian alternative splicing , 2005, The EMBO journal.

[66]  F. Clark,et al.  Understanding alternative splicing: towards a cellular code , 2005, Nature Reviews Molecular Cell Biology.

[67]  P. Rudland,et al.  Identification of mRNAs differentially-expressed between benign and malignant breast tumour cells , 2002, British Journal of Cancer.

[68]  S. Jang,et al.  Protein-protein interaction among hnRNPs shuttling between nucleus and cytoplasm. , 2000, Journal of molecular biology.

[69]  D. Capello,et al.  AP-2 transcription factors in the regulation of ERBB2 gene transcription by oestrogen , 2000, Oncogene.

[70]  C. Burd,et al.  RNA binding specificity of hnRNP A1: significance of hnRNP A1 high‐affinity binding sites in pre‐mRNA splicing. , 1994, The EMBO journal.

[71]  R. Persson,et al.  Locked nucleic acid: modality, diversity, and drug discovery. , 2018, Drug discovery today.

[72]  C. Lottaz,et al.  BIOINFORMATICS APPLICATIONS NOTE , 2001 .